| Q35018692 | A GSK-3β inhibitor protects against radiation necrosis in mouse brain |
| Q38258171 | A colorful history: the evolution of indigoids. |
| Q30458968 | Activation of GABA(B) receptors inhibits protein kinase B/glycogen synthase kinase 3 signaling |
| Q37728532 | Activation of muscarinic receptors inhibits glutamate-induced GSK-3β overactivation in PC12 cells |
| Q38592451 | Behind the curtain of tauopathy: a show of multiple players orchestrating tau toxicity |
| Q27315944 | Circumventing embryonic lethality with Lcmt1 deficiency: generation of hypomorphic Lcmt1 mice with reduced protein phosphatase 2A methyltransferase expression and defects in insulin signaling |
| Q42135408 | Deconstructing GSK-3: The Fine Regulation of Its Activity |
| Q38778638 | Defeating Alzheimer's disease and other dementias: a priority for European science and society |
| Q38230391 | Dietary regulation of PI3K/AKT/GSK-3β pathway in Alzheimer's disease |
| Q34071884 | Different susceptibility to neurodegeneration of dorsal and ventral hippocampal dentate gyrus: a study with transgenic mice overexpressing GSK3β. |
| Q49333511 | Disparate Effects of Lithium and a GSK-3 Inhibitor on Neuronal Oscillatory Activity in Prefrontal Cortex and Hippocampus |
| Q24610904 | Evidence for irreversible inhibition of glycogen synthase kinase-3β by tideglusib |
| Q38306065 | Further understanding of tau phosphorylation: implications for therapy. |
| Q35972878 | Future Therapeutics in Alzheimer's Disease: Development Status of BACE Inhibitors. |
| Q38673149 | GSK-3β deletion in dentate gyrus excitatory neuron impairs synaptic plasticity and memory |
| Q21285144 | GSK-3β: A Bifunctional Role in Cell Death Pathways |
| Q48005072 | Gender difference in valproic acid-induced neuroprotective effects on APP/PS1 double transgenic mice modeling Alzheimer's disease |
| Q39728463 | Glycogen synthase kinase 3 inhibitors in the next horizon for Alzheimer's disease treatment |
| Q38272835 | Glycogen synthase kinase-3 (GSK3): regulation, actions, and diseases |
| Q36335972 | Glycogen synthase kinase-3β regulates tumor necrosis factor-related apoptosis inducing ligand (TRAIL)-induced apoptosis via the NF-κB pathway in hepatocellular carcinoma |
| Q42759595 | Inhibition of glycogen synthase kinase-3 increases the cytotoxicity of enzastaurin |
| Q48311391 | Kidins220 accumulates with tau in human Alzheimer's disease and related models: modulation of its calpain-processing by GSK3β/PP1 imbalance |
| Q38773662 | Mechanistic Studies of Antibody-Mediated Clearance of Tau Aggregates Using an ex vivo Brain Slice Model |
| Q37946881 | Modulation of GSK-3 as a Therapeutic Strategy on Tau Pathologies |
| Q37978196 | New drug targets in depression: inflammatory, cell-mediated immune, oxidative and nitrosative stress, mitochondrial, antioxidant, and neuroprogressive pathways. And new drug candidates--Nrf2 activators and GSK-3 inhibitors. |
| Q38149943 | New insights into the role of glycogen synthase kinase-3 in Alzheimer's disease. |
| Q51533923 | Parkin differently regulates presenilin-1 and presenilin-2 functions by direct control of their promoter transcription. |
| Q26858851 | Platelet biomarkers in Alzheimer's disease |
| Q39393192 | Stable mutated tau441 transfected SH-SY5Y cells as screening tool for Alzheimer's disease drug candidates |
| Q26859305 | Successful therapies for Alzheimer's disease: why so many in animal models and none in humans? |
| Q37256805 | Tau oligomers as potential targets for Alzheimer's diagnosis and novel drugs |
| Q41985456 | Tau pathogenesis is promoted by Aβ1-42 but not Aβ1-40. |
| Q38101982 | Understanding the relationship between GSK-3 and Alzheimer's disease: a focus on how GSK-3 can modulate synaptic plasticity processes |
| Q50707979 | Valproic Acid Modifies Synaptic Structure and Accelerates Neurite Outgrowth Via the Glycogen Synthase Kinase-3β Signaling Pathway in an Alzheimer's Disease Model. |
| Q38034060 | What have we learned from the streptozotocin-induced animal model of sporadic Alzheimer's disease, about the therapeutic strategies in Alzheimer's research |